MILANO – Day to forget on the stock market for New Nordsik. The Danish pharmaceutical company, which has become the largest European company by market value thanks to the success of its anti-obesity drugs, collapsed today on the stock market after the announcement of the main results of tests on a new weight loss drug, considered below expectations by investors. At around 12.45 pm, the Danish pharmaceutical company suffered a decline of 19.4% to 598.90 crowns, after having also lost 27%, falling to August 2023 levels, in what is currently its worst trading day since April 2002.
The Novo Nordisk paradox: it drags the Danish economy but empties other companies of employees
by Emma Bonotti
December 17, 2024
Novo Nordisk released key data from the redefine 1 study, a phase 3 trial of the experimental drug cagrisema, indicating that treated subjects achieved a 22.7 percent weight loss after 68 weeks, compared to a reduction of 11. 8% with cagrilintide, 16.1% with semaglutide and 2.3% with placebo alone. The operators point out that the objective was to achieve an average weight reduction of 25% with the new drug and therefore cagrisema remained below the target, with 22.7%.
Novo Nordisk specifies that in this regard, ‘40% of patients treated with cagrisema experienced a weight loss equal to or greater than 25% after 68 weeks, compared to 6% with cagrilintide, 16.2% with semaglutide and 0, 9% with placebo. The study involved 3,417 people who were obese or overweight, with one or more co-morbidities and an average weight of 106.9 kg at the start of the study.
What are we talking about when we talk about Ozempic
by Riccardo Staglianò
November 15, 2024
According to Novo Nordisk, the study met “its primary objective by demonstrating statistically significant and greater weight loss with cagrisema compared to placebo after 68 weeks.” Cagrisema combines semaglutide, the active ingredient in Wegovy and Ozempic, the company’s two now famous weight loss drugs, with cagrilintide, a hormone that provides a long-lasting feeling of satiety. Novo Nordisk was the first to launch anti-obesity drugs and is currently competing above all with the American Eli Lilly to dominate a market that has increased sevenfold in three years, reaching – according to available data – a worth $24 billion in 2023.
